Gr. Sarantis（SSA1）株式概要Gr.サランティスS.A.は、その子会社とともに、ギリシャ、ポルトガル、ポーランド、ルーマニア、ブルガリア、セルビア、ボスニア・ヘルツェゴビナ、北マケドニア、スロベニア、チェコ・スロバキア、ハンガリー、ウクライナで化粧品、家庭用品、医薬品の製造・販売を行っている。 詳細SSA1 ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長1/6過去の実績5/6財務の健全性6/6配当金4/6報酬当社が推定した公正価値より53.9%で取引されている 収益は年間9.73%増加すると予測されています 過去1年間で収益は15.3%増加しました リスク分析不安定な配当実績 すべてのリスクチェックを見るSSA1 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€14.5214.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0749m2016201920222025202620282031Revenue €748.7mEarnings €66.3mAdvancedSet Fair ValueView all narrativesGr. Sarantis S.A. 競合他社BeiersdorfSymbol: XTRA:BEIMarket cap: €15.9bJamieson WellnessSymbol: TSX:JWELMarket cap: CA$1.5bHonasa ConsumerSymbol: NSEI:HONASAMarket cap: ₹125.1bBellRing BrandsSymbol: NYSE:BRBRMarket cap: US$1.1b価格と性能株価の高値、安値、推移の概要Gr. Sarantis過去の株価現在の株価€14.5252週高値€15.4052週安値€11.98ベータ0.531ヶ月の変化0.28%3ヶ月変化-2.42%1年変化12.38%3年間の変化102.51%5年間の変化64.63%IPOからの変化1,025.80%最新ニュースBoard Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Executive Chairman Kyriakos Sarantis was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 08, 2026Gr. Sarantis S.A. announced Annual dividend of EUR 0.3925 per share payable on May 08, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.お知らせ • Jan 15+ 2 more updatesGr. Sarantis S.A. to Report Fiscal Year 2025 Results on Mar 11, 2026Gr. Sarantis S.A. announced that they will report fiscal year 2025 results on Mar 11, 2026お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 09, 2025Gr. Sarantis S.A. announced Annual dividend of EUR 0.2992 per share payable on May 09, 2025, ex-date on May 02, 2025 and record date on May 05, 2025.お知らせ • Feb 19Gr. Sarantis S.A. to Report Fiscal Year 2024 Results on Mar 12, 2025Gr. Sarantis S.A. announced that they will report fiscal year 2024 results After-Market on Mar 12, 2025お知らせ • Feb 04Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025.最新情報をもっと見るRecent updatesBoard Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Executive Chairman Kyriakos Sarantis was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 08, 2026Gr. Sarantis S.A. announced Annual dividend of EUR 0.3925 per share payable on May 08, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.お知らせ • Jan 15+ 2 more updatesGr. Sarantis S.A. to Report Fiscal Year 2025 Results on Mar 11, 2026Gr. Sarantis S.A. announced that they will report fiscal year 2025 results on Mar 11, 2026お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 09, 2025Gr. Sarantis S.A. announced Annual dividend of EUR 0.2992 per share payable on May 09, 2025, ex-date on May 02, 2025 and record date on May 05, 2025.お知らせ • Feb 19Gr. Sarantis S.A. to Report Fiscal Year 2024 Results on Mar 12, 2025Gr. Sarantis S.A. announced that they will report fiscal year 2024 results After-Market on Mar 12, 2025お知らせ • Feb 04Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025.Recent Insider Transactions • Sep 26Executive Chairman recently bought €544k worth of stockOn the 23rd of September, Kyriakos Sarantis bought around 50k shares on-market at roughly €10.88 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.Reported Earnings • Sep 06First half 2024 earnings released: EPS: €0.38 (vs €0.29 in 1H 2023)First half 2024 results: EPS: €0.38 (up from €0.29 in 1H 2023). Revenue: €302.6m (up 30% from 1H 2023). Net income: €24.3m (up 27% from 1H 2023). Profit margin: 8.0% (down from 8.3% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 6% per year.Buy Or Sell Opportunity • Jul 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.7% to €10.88. The fair value is estimated to be €13.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.Recent Insider Transactions • Jul 10Executive Chairman recently bought €110k worth of stockOn the 4th of July, Kyriakos Sarantis bought around 10k shares on-market at roughly €11.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €6.0m worth in shares.Buy Or Sell Opportunity • Jul 01Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.9% to €10.68. The fair value is estimated to be €13.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.Buy Or Sell Opportunity • Jun 12Now 21% undervaluedOver the last 90 days, the stock has risen 4.8% to €10.98. The fair value is estimated to be €13.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.Declared Dividend • Apr 26Dividend increased to €0.22Dividend of €0.22 is 50% higher than last year. Ex-date: 2nd May 2024 Payment date: 13th May 2024 Dividend yield will be 1.9%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (38% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 38% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Mar 30+ 1 more updateGr. Sarantis S.A. to Report First Half, 2024 Results on Sep 03, 2024Gr. Sarantis S.A. announced that they will report first half, 2024 results on Sep 03, 2024Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €11.00, the stock trades at a trailing P/E ratio of 19.4x. Average forward P/E is 20x in the Personal Products industry in Europe. Total returns to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.96 per share.Buy Or Sell Opportunity • Mar 12Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 21% to €9.62. The fair value is estimated to be €7.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%.Reported Earnings • Mar 12Full year 2023 earnings released: EPS: €0.59 (vs €0.39 in FY 2022)Full year 2023 results: EPS: €0.59 (up from €0.39 in FY 2022). Revenue: €482.2m (up 8.3% from FY 2022). Net income: €39.3m (up 50% from FY 2022). Profit margin: 8.2% (up from 5.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year.お知らせ • Mar 01Gr. Sarantis S.A. to Report Fiscal Year 2023 Results on Mar 11, 2024Gr. Sarantis S.A. announced that they will report fiscal year 2023 results on Mar 11, 2024お知らせ • Dec 01Gr. Sarantis S.A., Annual General Meeting, Dec 20, 2023Gr. Sarantis S.A., Annual General Meeting, Dec 20, 2023, at 15:00 E. Europe Standard Time. Location: 26 AMAROUSSIOU-HALANDRIOU STR. 151 25 MAROUSI Marousi Greeceお知らせ • Nov 01Gr. Sarantis S.A. to Report Nine Months, 2023 Results on Nov 07, 2023Gr. Sarantis S.A. announced that they will report nine months, 2023 results on Nov 07, 2023New Risk • Oct 26New major risk - Revenue and earnings growthEarnings have declined by 2.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.2% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (3.7% increase in shares outstanding).Reported Earnings • Sep 14First half 2023 earnings released: EPS: €0.29 (vs €0.17 in 1H 2022)First half 2023 results: EPS: €0.29 (up from €0.17 in 1H 2022). Revenue: €232.4m (up 9.2% from 1H 2022). Net income: €19.2m (up 66% from 1H 2022). Profit margin: 8.3% (up from 5.4% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Aug 29Gr. Sarantis S.A. to Report First Half, 2023 Results on Sep 11, 2023Gr. Sarantis S.A. announced that they will report first half, 2023 results on Sep 11, 2023New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (4.4% increase in shares outstanding).Reported Earnings • Mar 29Full year 2022 earnings releasedFull year 2022 results: Revenue: €445.1m (up 9.0% from FY 2021). Net income: €26.3m (down 35% from FY 2021). Profit margin: 5.9% (down from 9.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Personal Products industry in Europe.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Nikos Nomikos was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 11First half 2022 earnings released: EPS: €0.17 (vs €0.22 in 1H 2021)First half 2022 results: EPS: €0.17 (down from €0.22 in 1H 2021). Revenue: €213.5m (up 9.3% from 1H 2021). Net income: €11.6m (down 21% from 1H 2021). Profit margin: 5.4% (down from 7.5% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • Aug 25Gr. Sarantis S.A. to Report First Half, 2022 Results on Sep 08, 2022Gr. Sarantis S.A. announced that they will report first half, 2022 results on Sep 08, 2022Reported Earnings • May 05Full year 2021 earnings released: EPS: €0.60 (vs €0.58 in FY 2020)Full year 2021 results: EPS: €0.60 (up from €0.58 in FY 2020). Revenue: €408.2m (up 3.8% from FY 2020). Net income: €40.3m (up 4.0% from FY 2020). Profit margin: 9.9% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.0%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Nikos Nomikos was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 12Gr. Sarantis S.A., Annual General Meeting, May 24, 2022Gr. Sarantis S.A., Annual General Meeting, May 24, 2022.お知らせ • Apr 05Gr. Sarantis S.A. to Report Fiscal Year 2021 Results on Apr 29, 2022Gr. Sarantis S.A. announced that they will report fiscal year 2021 results on Apr 29, 2022Recent Insider Transactions • Mar 30CEO & Director recently sold €2.0m worth of stockOn the 23rd of March, Kyriakos Sarantis sold around 265k shares on-market at roughly €7.50 per share. This was the largest sale by an insider in the last 3 months. Despite the recent sale, Kyriakos has been a buyer over the last 12 months, purchasing a net total of €2.2m worth of shares.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €7.35, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 27x in the Personal Products industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.65 per share.Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €7.01, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 28x in the Personal Products industry in Europe. Total returns to shareholders of 3.8% over the past three years.Board Change • Jan 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Nikos Nomikos was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Recent Insider Transactions • Dec 10Vice Chairman & CEO recently bought €86k worth of stockOn the 1st of December, Kyriakos Sarantis bought around 10k shares on-market at roughly €8.61 per share. In the last 3 months, they made an even bigger purchase worth €248k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €4.4m worth in shares.お知らせ • Dec 05Gr. Sarantis S.A. (ATSE:SAR) announces an Equity Buyback for 4,222,844 shares, representing 6.04% for €63.34 million.Gr. Sarantis S.A. (ATSE:SAR) commences share repurchases on December 2, 2021, under the program mandated by the shareholders in the Extraordinary Shareholders Meeting held on September 2, 2020. As per the mandate, the company is authorized to repurchase up to 4,222,844 shares representing 6.04% of the company's outstanding shares after excluding treasury shares for a total of €63.34 million. The maximum buy back price will be at €15 per share and the minimum is €0.78 per share. The purpose of the program is to serve the objectives and uses permitted by law from time to time, which today include share capital reduction, settlement of obligations arising by convertible securities or employee stock options as well as the purposes of future acquisition of another company’s shares. The repurchase program will be valid for 24 months, until September 2, 2022.Recent Insider Transactions • Nov 10Vice Chairman & CEO recently bought €119k worth of stockOn the 5th of November, Kyriakos Sarantis bought around 14k shares on-market at roughly €8.63 per share. In the last 3 months, they made an even bigger purchase worth €248k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €4.2m worth in shares.Recent Insider Transactions • Oct 27Vice Chairman & CEO recently bought €248k worth of stockOn the 20th of October, Kyriakos Sarantis bought around 28k shares on-market at roughly €8.78 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €4.0m worth in shares.Reported Earnings • Sep 11First half 2021 earnings released: EPS €0.29 (vs €0.23 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €195.2m (up 6.3% from 1H 2020). Net income: €19.5m (up 25% from 1H 2020). Profit margin: 10.0% (up from 8.5% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 8% per year.Recent Insider Transactions • Jul 15Vice Chairman & CEO recently bought €61k worth of stockOn the 8th of July, Kyriakos Sarantis bought around 7k shares on-market at roughly €8.78 per share. In the last 3 months, they made an even bigger purchase worth €915k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €3.2m worth in shares.Recent Insider Transactions • Jun 12Vice Chairman & CEO recently bought €90k worth of stockOn the 7th of June, Kyriakos Sarantis bought around 10k shares on-market at roughly €8.80 per share. In the last 3 months, they made an even bigger purchase worth €915k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €3.2m worth in shares.Recent Insider Transactions • Jun 02Vice Chairman & CEO recently bought €915k worth of stockOn the 26th of May, Kyriakos Sarantis bought around 105k shares on-market at roughly €8.71 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €2.8m worth in shares.Recent Insider Transactions • May 23Vice Chairman & CEO recently bought €69k worth of stockOn the 18th of May, Kyriakos Sarantis bought around 8k shares on-market at roughly €8.75 per share. In the last 3 months, they made an even bigger purchase worth €217k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €2.0m worth in shares.Recent Insider Transactions • May 08Vice Chairman & CEO recently bought €217k worth of stockOn the 5th of May, Kyriakos Sarantis bought around 24k shares on-market at roughly €8.88 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €1.6m worth in shares.Reported Earnings • Apr 11Full year 2020 earnings released: EPS €0.58 (vs €0.57 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €393.4m (up 6.3% from FY 2019). Net income: €38.7m (up 1.9% from FY 2019). Profit margin: 9.8% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 06Gr. Sarantis S.A. to Report Fiscal Year 2020 Results on Apr 08, 2021Gr. Sarantis S.A. announced that they will report fiscal year 2020 results After-Market on Apr 08, 2021Recent Insider Transactions • Mar 05Vice Chairman & CEO recently bought €96k worth of stockOn the 25th of February, Kyriakos Sarantis bought around 11k shares on-market at roughly €9.05 per share. In the last 3 months, they made an even bigger purchase worth €118k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €1.3m worth in shares.Recent Insider Transactions • Feb 13Vice Chairman & CEO recently bought €118k worth of stockOn the 5th of February, Kyriakos Sarantis bought around 13k shares on-market at roughly €8.85 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €1.2m worth in shares.Is New 90 Day High Low • Jan 05New 90-day high: €9.27The company is up 5.0% from its price of €8.84 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.26 per share.Recent Insider Transactions • Dec 16Vice Chairman & CEO recently bought €51k worth of stockOn the 10th of December, Kyriakos Sarantis bought around 6k shares on-market at roughly €8.74 per share. In the last 3 months, they made an even bigger purchase worth €69k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €474k worth in shares.お知らせ • Sep 22Mehmet Yigit Sardan will acquire 15% interest in Sarantis Anadol from Sarantis.Mehmet Yigit Sardan will acquire 15% interest in Sarantis Anadol from Sarantis on September 28, 2006.お知らせ • Sep 06Gr. Sarantis S.A. Not to Provide Financial Guidance for the Fiscal Year of 2020Gr. Sarantis S.A. is not provide financial guidance for the fiscal year of 2020 as it is not able to make accurate predictions at the time due to the continuing high uncertainty regarding the impact of COVID-19 on the economy, the consumption and the disposable income.お知らせ • Aug 03Gr. Sarantis S.A. to Report First Half, 2020 Results on Sep 02, 2020Gr. Sarantis S.A. announced that they will report first half, 2020 results on Sep 02, 2020株主還元SSA1DE Personal ProductsDE 市場7D-3.1%0.9%3.2%1Y12.4%-11.7%2.5%株主還元を見る業界別リターン: SSA1過去 1 年間で-11.7 % の収益を上げたGerman Personal Products業界を上回りました。リターン対市場: SSA1過去 1 年間で2.5 % の収益を上げたGerman市場を上回りました。価格変動Is SSA1's price volatile compared to industry and market?SSA1 volatilitySSA1 Average Weekly Movement4.4%Personal Products Industry Average Movement5.2%Market Average Movement6.1%10% most volatile stocks in DE Market13.6%10% least volatile stocks in DE Market2.7%安定した株価: SSA1 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: SSA1の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19303,042Giannis Bourassarantisgroup.comGr.サランティスS.A.は子会社とともに、ギリシャ、ポルトガル、ポーランド、ルーマニア、ブルガリア、セルビア、ボスニア・ヘルツェゴビナ、北マケドニア、スロベニア、チェコ・スロバキア、ハンガリー、ウクライナで化粧品、家庭用品、医薬品の製造・販売を行っている。ビューティ/スキンケア/サンケア、パーソナルケア、ホームケアソリューション、プライベートブランド、戦略的パートナーシップ、その他の販売分野で事業を展開している。同社は、食品サプリメント、ヘルス＆セルフケア、ベビーケア、ボディソープ、デオドラント、フレグランス、グルーミング、ヘアケア＆スタイリング、ハンドソープ、オーラルケア、パーソナルハイジーン、スキンケア＆サンケアなどのパーソナルケアおよびヘルスケア製品を提供している。また、掃除用具、洗剤、包装、浴室用クリーナー、濃縮柔軟剤、食器洗い、排水口ケア、食品包装、プラスチックゴミ袋、防虫剤、浄化槽活性剤、靴ケアなどのホームケアおよびプロフェッショナル製品、キャンドル、ホームフレグランス、メイクアップ、トリートメントなどの高級化粧品も提供している。同社はハイパーマーケット、スーパーマーケット、食料品店、美容室、薬局などを通じて製品を提供している。Gr.サランティス社は1930年に設立され、ギリシャのアテネに本社を置いている。もっと見るGr. Sarantis S.A. 基礎のまとめGr. Sarantis の収益と売上を時価総額と比較するとどうか。SSA1 基礎統計学時価総額€930.53m収益（TTM）€53.06m売上高(TTM)€599.56m17.5xPER（株価収益率1.6xP/SレシオSSA1 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SSA1 損益計算書（TTM）収益€599.56m売上原価€376.90m売上総利益€222.66mその他の費用€169.60m収益€53.06m直近の収益報告Dec 31, 2025次回決算日Sep 08, 2026一株当たり利益（EPS）0.84グロス・マージン37.14%純利益率8.85%有利子負債／自己資本比率10.5%SSA1 の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.7%現在の配当利回り47%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:15終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gr. Sarantis S.A. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関Manos ChatzidakisBeta Securities S.A.Dimitris GiannoulisDeutsche BankNatalia Svyrou SvyriadiEurobank Equities Investment Firm S.A.9 その他のアナリストを表示
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Executive Chairman Kyriakos Sarantis was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 08, 2026Gr. Sarantis S.A. announced Annual dividend of EUR 0.3925 per share payable on May 08, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
お知らせ • Jan 15+ 2 more updatesGr. Sarantis S.A. to Report Fiscal Year 2025 Results on Mar 11, 2026Gr. Sarantis S.A. announced that they will report fiscal year 2025 results on Mar 11, 2026
お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 09, 2025Gr. Sarantis S.A. announced Annual dividend of EUR 0.2992 per share payable on May 09, 2025, ex-date on May 02, 2025 and record date on May 05, 2025.
お知らせ • Feb 19Gr. Sarantis S.A. to Report Fiscal Year 2024 Results on Mar 12, 2025Gr. Sarantis S.A. announced that they will report fiscal year 2024 results After-Market on Mar 12, 2025
お知らせ • Feb 04Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025.
Board Change • May 20High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Executive Chairman Kyriakos Sarantis was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 08, 2026Gr. Sarantis S.A. announced Annual dividend of EUR 0.3925 per share payable on May 08, 2026, ex-date on May 04, 2026 and record date on May 05, 2026.
お知らせ • Jan 15+ 2 more updatesGr. Sarantis S.A. to Report Fiscal Year 2025 Results on Mar 11, 2026Gr. Sarantis S.A. announced that they will report fiscal year 2025 results on Mar 11, 2026
お知らせ • Mar 13Gr. Sarantis S.A. announces Annual dividend, payable on May 09, 2025Gr. Sarantis S.A. announced Annual dividend of EUR 0.2992 per share payable on May 09, 2025, ex-date on May 02, 2025 and record date on May 05, 2025.
お知らせ • Feb 19Gr. Sarantis S.A. to Report Fiscal Year 2024 Results on Mar 12, 2025Gr. Sarantis S.A. announced that they will report fiscal year 2024 results After-Market on Mar 12, 2025
お知らせ • Feb 04Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025Gr. Sarantis S.A., Annual General Meeting, Apr 28, 2025.
Recent Insider Transactions • Sep 26Executive Chairman recently bought €544k worth of stockOn the 23rd of September, Kyriakos Sarantis bought around 50k shares on-market at roughly €10.88 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.
Reported Earnings • Sep 06First half 2024 earnings released: EPS: €0.38 (vs €0.29 in 1H 2023)First half 2024 results: EPS: €0.38 (up from €0.29 in 1H 2023). Revenue: €302.6m (up 30% from 1H 2023). Net income: €24.3m (up 27% from 1H 2023). Profit margin: 8.0% (down from 8.3% in 1H 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 6% per year.
Buy Or Sell Opportunity • Jul 22Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.7% to €10.88. The fair value is estimated to be €13.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.
Recent Insider Transactions • Jul 10Executive Chairman recently bought €110k worth of stockOn the 4th of July, Kyriakos Sarantis bought around 10k shares on-market at roughly €11.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €6.0m worth in shares.
Buy Or Sell Opportunity • Jul 01Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.9% to €10.68. The fair value is estimated to be €13.45, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings are also forecast to grow by 13% per annum over the same time period.
Buy Or Sell Opportunity • Jun 12Now 21% undervaluedOver the last 90 days, the stock has risen 4.8% to €10.98. The fair value is estimated to be €13.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
Declared Dividend • Apr 26Dividend increased to €0.22Dividend of €0.22 is 50% higher than last year. Ex-date: 2nd May 2024 Payment date: 13th May 2024 Dividend yield will be 1.9%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (38% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 4.1% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 38% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Mar 30+ 1 more updateGr. Sarantis S.A. to Report First Half, 2024 Results on Sep 03, 2024Gr. Sarantis S.A. announced that they will report first half, 2024 results on Sep 03, 2024
Valuation Update With 7 Day Price Move • Mar 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €11.00, the stock trades at a trailing P/E ratio of 19.4x. Average forward P/E is 20x in the Personal Products industry in Europe. Total returns to shareholders of 36% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.96 per share.
Buy Or Sell Opportunity • Mar 12Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 21% to €9.62. The fair value is estimated to be €7.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Earnings per share has declined by 2.7%.
Reported Earnings • Mar 12Full year 2023 earnings released: EPS: €0.59 (vs €0.39 in FY 2022)Full year 2023 results: EPS: €0.59 (up from €0.39 in FY 2022). Revenue: €482.2m (up 8.3% from FY 2022). Net income: €39.3m (up 50% from FY 2022). Profit margin: 8.2% (up from 5.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year.
お知らせ • Mar 01Gr. Sarantis S.A. to Report Fiscal Year 2023 Results on Mar 11, 2024Gr. Sarantis S.A. announced that they will report fiscal year 2023 results on Mar 11, 2024
お知らせ • Dec 01Gr. Sarantis S.A., Annual General Meeting, Dec 20, 2023Gr. Sarantis S.A., Annual General Meeting, Dec 20, 2023, at 15:00 E. Europe Standard Time. Location: 26 AMAROUSSIOU-HALANDRIOU STR. 151 25 MAROUSI Marousi Greece
お知らせ • Nov 01Gr. Sarantis S.A. to Report Nine Months, 2023 Results on Nov 07, 2023Gr. Sarantis S.A. announced that they will report nine months, 2023 results on Nov 07, 2023
New Risk • Oct 26New major risk - Revenue and earnings growthEarnings have declined by 2.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.2% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (3.7% increase in shares outstanding).
Reported Earnings • Sep 14First half 2023 earnings released: EPS: €0.29 (vs €0.17 in 1H 2022)First half 2023 results: EPS: €0.29 (up from €0.17 in 1H 2022). Revenue: €232.4m (up 9.2% from 1H 2022). Net income: €19.2m (up 66% from 1H 2022). Profit margin: 8.3% (up from 5.4% in 1H 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 29Gr. Sarantis S.A. to Report First Half, 2023 Results on Sep 11, 2023Gr. Sarantis S.A. announced that they will report first half, 2023 results on Sep 11, 2023
New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (4.4% increase in shares outstanding).
Reported Earnings • Mar 29Full year 2022 earnings releasedFull year 2022 results: Revenue: €445.1m (up 9.0% from FY 2021). Net income: €26.3m (down 35% from FY 2021). Profit margin: 5.9% (down from 9.9% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Personal Products industry in Europe.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Nikos Nomikos was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 11First half 2022 earnings released: EPS: €0.17 (vs €0.22 in 1H 2021)First half 2022 results: EPS: €0.17 (down from €0.22 in 1H 2021). Revenue: €213.5m (up 9.3% from 1H 2021). Net income: €11.6m (down 21% from 1H 2021). Profit margin: 5.4% (down from 7.5% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • Aug 25Gr. Sarantis S.A. to Report First Half, 2022 Results on Sep 08, 2022Gr. Sarantis S.A. announced that they will report first half, 2022 results on Sep 08, 2022
Reported Earnings • May 05Full year 2021 earnings released: EPS: €0.60 (vs €0.58 in FY 2020)Full year 2021 results: EPS: €0.60 (up from €0.58 in FY 2020). Revenue: €408.2m (up 3.8% from FY 2020). Net income: €40.3m (up 4.0% from FY 2020). Profit margin: 9.9% (in line with FY 2020). Over the next year, revenue is forecast to grow 9.0%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Nikos Nomikos was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 12Gr. Sarantis S.A., Annual General Meeting, May 24, 2022Gr. Sarantis S.A., Annual General Meeting, May 24, 2022.
お知らせ • Apr 05Gr. Sarantis S.A. to Report Fiscal Year 2021 Results on Apr 29, 2022Gr. Sarantis S.A. announced that they will report fiscal year 2021 results on Apr 29, 2022
Recent Insider Transactions • Mar 30CEO & Director recently sold €2.0m worth of stockOn the 23rd of March, Kyriakos Sarantis sold around 265k shares on-market at roughly €7.50 per share. This was the largest sale by an insider in the last 3 months. Despite the recent sale, Kyriakos has been a buyer over the last 12 months, purchasing a net total of €2.2m worth of shares.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €7.35, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 27x in the Personal Products industry in Europe. Total returns to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.65 per share.
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €7.01, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 28x in the Personal Products industry in Europe. Total returns to shareholders of 3.8% over the past three years.
Board Change • Jan 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Nikos Nomikos was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Recent Insider Transactions • Dec 10Vice Chairman & CEO recently bought €86k worth of stockOn the 1st of December, Kyriakos Sarantis bought around 10k shares on-market at roughly €8.61 per share. In the last 3 months, they made an even bigger purchase worth €248k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €4.4m worth in shares.
お知らせ • Dec 05Gr. Sarantis S.A. (ATSE:SAR) announces an Equity Buyback for 4,222,844 shares, representing 6.04% for €63.34 million.Gr. Sarantis S.A. (ATSE:SAR) commences share repurchases on December 2, 2021, under the program mandated by the shareholders in the Extraordinary Shareholders Meeting held on September 2, 2020. As per the mandate, the company is authorized to repurchase up to 4,222,844 shares representing 6.04% of the company's outstanding shares after excluding treasury shares for a total of €63.34 million. The maximum buy back price will be at €15 per share and the minimum is €0.78 per share. The purpose of the program is to serve the objectives and uses permitted by law from time to time, which today include share capital reduction, settlement of obligations arising by convertible securities or employee stock options as well as the purposes of future acquisition of another company’s shares. The repurchase program will be valid for 24 months, until September 2, 2022.
Recent Insider Transactions • Nov 10Vice Chairman & CEO recently bought €119k worth of stockOn the 5th of November, Kyriakos Sarantis bought around 14k shares on-market at roughly €8.63 per share. In the last 3 months, they made an even bigger purchase worth €248k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €4.2m worth in shares.
Recent Insider Transactions • Oct 27Vice Chairman & CEO recently bought €248k worth of stockOn the 20th of October, Kyriakos Sarantis bought around 28k shares on-market at roughly €8.78 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €4.0m worth in shares.
Reported Earnings • Sep 11First half 2021 earnings released: EPS €0.29 (vs €0.23 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €195.2m (up 6.3% from 1H 2020). Net income: €19.5m (up 25% from 1H 2020). Profit margin: 10.0% (up from 8.5% in 1H 2020). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 8% per year.
Recent Insider Transactions • Jul 15Vice Chairman & CEO recently bought €61k worth of stockOn the 8th of July, Kyriakos Sarantis bought around 7k shares on-market at roughly €8.78 per share. In the last 3 months, they made an even bigger purchase worth €915k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €3.2m worth in shares.
Recent Insider Transactions • Jun 12Vice Chairman & CEO recently bought €90k worth of stockOn the 7th of June, Kyriakos Sarantis bought around 10k shares on-market at roughly €8.80 per share. In the last 3 months, they made an even bigger purchase worth €915k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €3.2m worth in shares.
Recent Insider Transactions • Jun 02Vice Chairman & CEO recently bought €915k worth of stockOn the 26th of May, Kyriakos Sarantis bought around 105k shares on-market at roughly €8.71 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €2.8m worth in shares.
Recent Insider Transactions • May 23Vice Chairman & CEO recently bought €69k worth of stockOn the 18th of May, Kyriakos Sarantis bought around 8k shares on-market at roughly €8.75 per share. In the last 3 months, they made an even bigger purchase worth €217k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €2.0m worth in shares.
Recent Insider Transactions • May 08Vice Chairman & CEO recently bought €217k worth of stockOn the 5th of May, Kyriakos Sarantis bought around 24k shares on-market at roughly €8.88 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €1.6m worth in shares.
Reported Earnings • Apr 11Full year 2020 earnings released: EPS €0.58 (vs €0.57 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: €393.4m (up 6.3% from FY 2019). Net income: €38.7m (up 1.9% from FY 2019). Profit margin: 9.8% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 06Gr. Sarantis S.A. to Report Fiscal Year 2020 Results on Apr 08, 2021Gr. Sarantis S.A. announced that they will report fiscal year 2020 results After-Market on Apr 08, 2021
Recent Insider Transactions • Mar 05Vice Chairman & CEO recently bought €96k worth of stockOn the 25th of February, Kyriakos Sarantis bought around 11k shares on-market at roughly €9.05 per share. In the last 3 months, they made an even bigger purchase worth €118k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €1.3m worth in shares.
Recent Insider Transactions • Feb 13Vice Chairman & CEO recently bought €118k worth of stockOn the 5th of February, Kyriakos Sarantis bought around 13k shares on-market at roughly €8.85 per share. This was the largest purchase by an insider in the last 3 months. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €1.2m worth in shares.
Is New 90 Day High Low • Jan 05New 90-day high: €9.27The company is up 5.0% from its price of €8.84 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.26 per share.
Recent Insider Transactions • Dec 16Vice Chairman & CEO recently bought €51k worth of stockOn the 10th of December, Kyriakos Sarantis bought around 6k shares on-market at roughly €8.74 per share. In the last 3 months, they made an even bigger purchase worth €69k. Kyriakos has been a buyer over the last 12 months, purchasing a net total of €474k worth in shares.
お知らせ • Sep 22Mehmet Yigit Sardan will acquire 15% interest in Sarantis Anadol from Sarantis.Mehmet Yigit Sardan will acquire 15% interest in Sarantis Anadol from Sarantis on September 28, 2006.
お知らせ • Sep 06Gr. Sarantis S.A. Not to Provide Financial Guidance for the Fiscal Year of 2020Gr. Sarantis S.A. is not provide financial guidance for the fiscal year of 2020 as it is not able to make accurate predictions at the time due to the continuing high uncertainty regarding the impact of COVID-19 on the economy, the consumption and the disposable income.
お知らせ • Aug 03Gr. Sarantis S.A. to Report First Half, 2020 Results on Sep 02, 2020Gr. Sarantis S.A. announced that they will report first half, 2020 results on Sep 02, 2020
